The DOI matches its Crossref record; 38 of the 40 references it cites were found in a registry or an index.
Metformin Is Associated With Higher Relative Abundance of Mucin-Degrading Akkermansia muciniphila and Several Short-Chain Fatty Acid–Producing Microbiota in the Gut
Abstract
OBJECTIVE: Recent studies suggest the beneficial effects of metformin on glucose metabolism may be microbially mediated. We examined the association of type 2 diabetes, metformin, and gut microbiota in community-dwelling Colombian adults. On the basis of previous research, we hypothesized that metformin is associated with higher levels of short-chain fatty acid (SCFA)–producing and mucin-degrading microbiota. RESEARCH DESIGN AND METHODS: Participants were selected from a larger cohort of 459 participants. The present analyses focus on the 28 participants diagnosed with diabetes—14 taking metformin— and the 84 participants without diabetes who were matched (3-to-1) to participants with diabetes by sex, age, and BMI. We measured demographic information, anthropometry, and blood biochemical parameters and collected fecal samples from which we performed 16S rRNA gene sequencing to analyze the composition and structure of the gut microbiota. RESULTS: We found an association between diabetes and gut microbiota that was modified by metformin use. Compared with participants without diabetes, participants with diabetes taking metformin had higher relative abundance of Akkermansia muciniphila, a microbiota known for mucin degradation, and several gut microbiota known for production of SCFAs, including Butyrivibrio, Bifidobacterium bifidum, Megasphaera, and an operational taxonomic unit of Prevotella. In contrast, compared with participants without diabetes, participants with diabetes not taking metformin had higher relative abundance of Clostridiaceae 02d06 and a distinct operational taxonomic unit of Prevotella and a lower abundance of Enterococcus casseliflavus. CONCLUSIONS: Our results support the hypothesis that metformin shifts gut microbiota composition through the enrichment of mucin-degrading A. muciniphila as well as several SCFA-producing microbiota. Future studies are needed to determine if these shifts mediate metformin’s glycemic and anti-inflammatory properties.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Biguanides/metformin, the first-line therapeutics for T2D, modifies microbiota leading to an increase in A. muciniphila, as well as several SCFA-producing microbiota, favoring an improvement on mucin-producing goblet cells, pro-inflammatory IL-6, and glucose tolerance [304].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [304]
In the citing paper
“In human diabetic individuals, metformin was shown to shift gut microbiota composition to predominantly short-chain fatty-acid producing microbes”
From Benefits of Metformin in Attenuating the Hallmarks of Aging (2020) · cites this paper as de la Cuesta-Zuluaga et al. 2017
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
Schloss, P. D., Westcott, S. L., Ryabin, T., Hall, J. R., Hartmann, M., Hollister, E. B., Lesniewski, R. A., Oakley, B. B., Parks, D. H., Robinson, C. J., et al. (2009) · Applied and Environmental Microbiology · doi:10.1128/aem.01541-09 · Cited by 19,549
Metagenomic biomarker discovery and explanation
Segata, N., Izard, J., Waldron, L., Gevers, D., Miropolsky, L., Garrett, W. S., & Huttenhower, C. (2011) · Genome Biology · doi:10.1186/gb-2011-12-6-r60 · Cited by 16,192 · cited 2×
“pairwise tests among groups of participants using the unpaired Wilcoxon rank sum test, and finally uses LDA to estimate the effect size of each differentially abundant OTU (24).”
MethodKozich, J. J., Westcott, S. L., Baxter, N. T., Highlander, S. K., & Schloss, P. D. (2013) · Applied and Environmental Microbiology · doi:10.1128/aem.01043-13 · Cited by 7,112
A metagenome-wide association study of gut microbiota in type 2 diabetes
Qin, J., Li, Y., Cai, Z., Li, S., Zhu, J., Zhang, F., Liang, S., Zhang, W., Guan, Y., Shen, D., et al. (2012) · Nature · doi:10.1038/nature11450 · Cited by 6,762 · cited 1×
“Given the considerable variation in the microbiota associated with type 2 diabetes and that the gut microbiota of Colombians is different to that of other populations (18), we hypothesized that the microbial taxa involved in the type 2 diabetes dysbiosis of Colombians are different to those observed in Chinese and Eur…”
BackgroundLinking long-term dietary patterns with gut microbial enterotypes
Wu, G. D., Chen, J., Hoffmann, C., Bittinger, K., Chen, Y.-Y., Keilbaugh, S. A., Bewtra, M., Knights, D., Walters, W. A., Knight, R., et al. (2011) · Science · doi:10.1126/science.1208344 · Cited by 6,513 · cited 1×
“Prevotella has been associated with carbohydrate-baseddiets anddegradation of complex polysaccharides (26), whereas E.”
BackgroundCross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity
Everard, A., Belzer, C., Geurts, L., Ouwerkerk, J. P., Druart, C., Bindels, L. B., Guiot, Y., Derrien, M., Muccioli, G. G., Delzenne, N. M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219451110 · Cited by 4,511 · cited 3×
“abundance of Akkermansia muciniphila (11–13), a mucin-degrading bacteria that has been shown to reverse metabolic disorders (1,12).”
BackgroundInfluentialGut metagenome in European women with normal, impaired and diabetic glucose control
Karlsson, F. H., Tremaroli, V., Nookaew, I., Bergström, G., Behre, C. J., Fagerberg, B., Nielsen, J., & Bäckhed, F. (2013) · Nature · doi:10.1038/nature12198 · Cited by 3,115 · cited 1×
“Given the considerable variation in the microbiota associated with type 2 diabetes and that the gut microbiota of Colombians is different to that of other populations (18), we hypothesized that the microbial taxa involved in the type 2 diabetes dysbiosis of Colombians are different to those observed in Chinese and Eur…”
BackgroundGut Microbiota in Human Adults with Type 2 Diabetes Differs from Non-Diabetic Adults
Larsen, N., Vogensen, F. K., van den Berg, F. W. J., Nielsen, D. S., Andreasen, A. S., Pedersen, B. K., Al-Soud, W. A., Sørensen, S. J., Hansen, L. H., & Jakobsen, M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009085 · Cited by 2,952
Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism
Wahlström, A., Sayin, S. I., Marschall, H.-U., & Bäckhed, F. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.05.005 · Cited by 2,851 · cited 1×
“through effects on bile acid secretion (31).”
Cited by
Items 601–700 of 731
Anti‐Diabetic Intestinal Mechanisms: Foods, Herbs, and Western Medicines
Feng, Y., Cao, H., Hua, J., & Zhang, F. (2022) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202200106 · Cited by 2
Microbiota and epigenetics: Health impact
Ahrodia, T., Kandiyal, B., & Das, B. (2023) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2023.03.018 · Cited by 3
Mysterious Akkermansia muciniphila. What do we know about it? A review
Zakharova, I. N., Berezhnaya, I. V., Dubovets, N. F., Владимировна, С. Е., Dubovets, E. A., & Dubovets, A. A. (2023) · Pediatrics Consilium Medicum · doi:10.26442/26586630.2023.1.202190 · Cited by 2
Microbiome-Targeted Therapies: Enhancing Resilience in Metabolic Disorders
Janiad, S., & Rehman, K. (2024) · Springer eBooks · doi:10.1007/978-981-97-3790-1_13 · Cited by 2
Pizarro, R. R. M., de Guzman, M., Gururagavendiran, S., Mariados, S. W., Deb, S., & Allan, R. B. P. V. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15435-5.00006-2 · Cited by 1
Regulation of Gut Microbiota a Potential Therapeutic Option for Insulin Resistance - A Review
Vasudeva, V. (2025) · International journal of high school research · doi:10.36838/v7i7.82 · Cited by 1
Song, L., Wang, R., Cui, J., Hu, S., Wang, J., Xie, J., Miao, P., & Sun, B. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1650805 · Cited by 2
Hendesi, H., Godfrey, D. A., Ruble, A. F., Tran, A. M., Villani, D. A., Landgrave, S. H., Hasan, N. A., Adams, D. J., & Zuscik, M. J. (2025) · Bone Reports · doi:10.1016/j.bonr.2025.101876 · Cited by 3
Gündoğdu, A., Arıkan, M., Ulas, A., Koldaş, S. S., & Ece, G. T. (2025) · Next research. · doi:10.1016/j.nexres.2025.100846 · Cited by 3
Gut microbiota as a key player in type 2 diabetes: Current perspectives
Sethumadhavan, S., Jacob, S. M., & Babu, M. N. (2025) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2026.267236 · Cited by 1
“…conducted in Colombia discovered that metformin alleviated hyperglycemia and correlated positively with an increased presence of short-chain fatty acid (SCFA)-producing bacteria such as Butyrivibrio , Bifidobacterium bifidum , Megasphaera , and a specific group within Prevotella genus [8,17] .”
Metformin in skin diseases: the role of gut microbiota and immune response
Kiecka, A., Macura, B., & Szczepanik, M. (2026) · Pharmacological Reports · doi:10.1007/s43440-026-00825-x · Cited by 1
Li, Y., Xingqi, G., Dong, X., Xia, T., Ma, S., & Liu, Z. (2026) · iScience · doi:10.1016/j.isci.2026.114877 · Cited by 1
Tratnjek, L., Janev, A., Kuret, T., & Jerman, U. D. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1731784 · Cited by 1
Qumsani, A. T. (2026) · Journal of King Saud University - Science · doi:10.25259/jksus_1182_2025 · Cited by 1
Rajalakshmi, S. G., Babu, K. D., & Viswanathan, P. (2026) · Life Sciences · doi:10.1016/j.lfs.2026.124336 · Cited by 1
Role of diet in shaping the gut microbiome
Siddiqui, B., Tiwari, S., Fatima, S., & Abdin, M. Z. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-40483-2.00027-3
Szkamruk, Z., Cielecka, J., Walędziak, M., & Różańska-Walędziak, A. M. (2026) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.1007/s44411-026-00596-0 · Cited by 1
Kwiendacz, H., Cembrowska-Lech, D., Skonieczna‐Żydecka, K., Klimontowicz, K., Podsiadło, K., Wierzbicka-Woś, A., Styburski, D., Kaczmarczyk, M., Gumprecht, J., Łoniewski, I., et al. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119370 · Cited by 1
Wang, L., Liang, C., Yu, J., Zhang, Y., Li, H., Hu, Y., Liu, W., Qu, X., Xie, W., Wang, X., et al. (2026) · Food Research International · doi:10.1016/j.foodres.2026.119257 · Cited by 1
Romeo, M., Basile, C., Martinelli, G., Nardo, F. D., Napolitano, C., Gregorio, A. D., Vaia, P., Puorto, L. D., Indipendente, M., Federico, A., et al. (2026) · Cancers · doi:10.3390/cancers18081316 · Cited by 1
Gut microbial metabolites for potentiating cancer therapy
Kamrad, S., Gagliani, N., Lawley, T. D., Patil, K. R., & Tintelnot, J. (2026) · Trends in cancer · doi:10.1016/j.trecan.2026.04.005 · Cited by 2
Metformin at the convergence of aging and longevity
Manneh, J., Alasmar, M., & Hajj, N. E. (2026) · Aging · doi:10.18632/aging.206407 · Cited by 1
Pharmacomicrobiomics in metabolic syndrome and type 2 diabetes: the microbiome–drug–host triad
Strilić, D., Stanimirov, B., Pavlović, N., Lazarević, S., Mikov, M., Stanivukovic, T., & Đanić, M. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1831882 · Cited by 1
Obstetric Pharmacomicrobiomics
Eke, A. C. (2026) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70520 · Cited by 1
Wunderlich, M., Miller, M., Ritter, B., Gleut, R. L., Marchi, H., Majzoub‐Altweck, M., Knerr, P. J., Douros, J. D., Müller, T. D., & Brielmeier, M. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.101992 · Cited by 1
“Diabetes medication and gut microbiome in fl uence each other, e.g. metformin or liraglutide [45 e 51].”
BackgroundAre non-communicable diseases chronically communicable: A role for the human microbiota?
Abbasi, A. (2017) · Medical Hypotheses · doi:10.1016/j.mehy.2017.06.002 · Cited by 1
Liu, Y.-K., Xu, X., & Zhou, X. (2019) · PubMed · doi:10.7518/hxkq.2019.05.020 · Cited by 1
“[67] de la CuestaZuluaga J, Mueller NT, CorralesAgudelo V, et al.”
The Amount of Residual Incretin Regulates the Pancreatic β-cell Function and Glucose Homeostasis
Kondo, T., Kitano, S., Miyakawa, N., Watanabe, T., Goto, R., Sato, M., Hanatani, S., Sakaguchi, M., Igata, M., Kawashima, J., et al. (2021) · Internal Medicine · doi:10.2169/internalmedicine.6026-20 · Cited by 1
“Since metformin was suggested to potentially have beneficial effects on the gut microbiota (13), 1,000 mg of metformin was added, but his glucose levels failed to be controlled.”
BackgroundSilva, P. H., de Freitas, L. D. B. R., dos Santos, S. M., do Carmo, T. L., Porto, A. L. F., Oliveira, V. D. M., Calaça, P. R. D. A., & Cavalcanti, M. T. H. (2021) · Research Society and Development · doi:10.33448/rsd-v10i8.17454 · Cited by 2
“No trabalho de De La Cuesta-Zuluaga et al. (2017), a utilização de metformina, composto utilizado por pacientes com diabete tipo 1, aumentou consideravelmente os níveis de A. muciniphila no intestino e, em decorrência desses acontecimentos, a mediação na redução de glicose poderia ser concretizada…”
BackgroundLitvinova, O., Posilkina, O., Kovalenko, S. H., Yeromenko, R. F., Братишко, Ю. С., & Лісна, А. Г. (2022) · ScienceRise Pharmaceutical Science · doi:10.15587/2519-4852.2022.255536 · Cited by 1
“Research data suggest that metformin interacts with various intestinal bacteria [5, 6].”
BackgroundImpact of the Gastrointestinal Tract Microbiota on Cardiovascular Health and Pathophysiology
Akyıldız, A. G., Biondi‐Zoccai, G., & Biase, D. D. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001273 · Cited by 1
13. Gut Microbiome and Cardiovascular Diseases
Hirata, K., & Yamashita, T. (2018) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.107.1906 · Cited by 1
Antidiabetic Drugs and their Potential Use in COVID-19: A Mechanistic Approach
Balderas-Rentería, I., Espinosa-Rodríguez, B. A., Nieto-Moreno, A. M., Llerena, J. L. G., Rico-Torres, T. A., Carranza‐Rosales, P., & Méndez-López, L. F. (2022) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530322666220516115604 · Cited by 1
Probiotics for diabetes mellitus: prevention and treatment
Moreno‐Indias, I., & Tinahones, F. J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-89908-6.00001-7 · Cited by 1
Lakshmanan, A. P., Murugesan, S., & Bangarusamy, D. K. (2022) · Springer eBooks · doi:10.1007/978-981-16-6226-3_4 · Cited by 1
Bhardwaj, M., & Yadav, M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99336-4.00007-0 · Cited by 1
Hieshima, K., Sugiyama, S., Yoshida, A., Kurinami, N., Suzuki, T., Otsuka, K., MIYAMOTO, F., Kajiwara, K., Jinnouchi, K., Jinnouchi, T., et al. (2023) · Journal of Endocrinology and Metabolism · doi:10.14740/jem916 · Cited by 1
Changes in the Gut Microbiome as Seen in Diabetes and Obesity
Barlow, G. M., Celly, S., & Mathur, R. (2023) · Springer eBooks · doi:10.1007/978-3-031-46712-7_5 · Cited by 1
Piłot, M., Dzięgielewska-Gęsiak, S., Wolińska-Grabowska, A., & Muc‐Wierzgoń, M. (2024) · Annales Academiae Medicae Silesiensis · doi:10.18794/aams/175109 · Cited by 1
“The number of publications on the effect of metformin on the gut microbiome is steadily increasing [33,34], while there are few reports on the effect of insulin or insulin/metformin treatment on the gut microbiome.”
BackgroundMetformin and intestinal microbiota
Григорьева, И. Н., Романова, Т. И., Станиславовна, С. Т., & Nepomnyashchikh, D. L. (2024) · Medical alphabet · doi:10.33667/2078-5631-2024-26-19-23 · Cited by 2
Akkermansia mucinifila and the part that it plays in metabolic disturbance
Fadieienko, G. D., & Gridnyev, O. (2020) · Ukrainian Therapeutical Journal · doi:10.30978/utj2020-4-55 · Cited by 2
The Role of Oligofructose in Altering Small Intestinal Nutrient Sensing via the Gut Microbiota
Weninger, S. N. (2020) · UA Campus Repository (The University of Arizona) · Cited by 1
Courtois, S. (2017) · theses.fr (ABES) · doi:10.70675/9cea7a12z80a2z4c42za889z55d1acdfaf97 · Cited by 1
Ist das Darmmikrobiom für die Wirkung von Metformin verantwortlich?
(2017) · Diabetologie und Stoffwechsel · doi:10.1055/s-0043-105425
Mechanism Development of Diabetic Microangiopathy and Opportunity of Diabetic Warning
Genyk, S. M. (2018) · Galician Medical Journal · doi:10.21802/gmj.2018.2.8
The effects of metformin on colorectal cancer growth and the involvement of the gut microbiome
Broadfield, L. A. (2018) · MacSphere (McMaster University) · doi:10.71548/9648
Die Rolle des Darm-Mikrobioms bei Adipositas und Typ-2-Diabetes
Siegel, E. G. (2019) · CardioVasc · doi:10.1007/s15027-019-1565-6
Garcés, M. A., & Leonor, B. (2018) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Impact drugs targeting cardiometabolic risk on the gut microbiota
Balvers, M., van den Born, B. H., Levin, E., & Nieuwdorp, M. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000727 · Cited by 1
“[59] Cross-sectional analysis of 28 Colombian T2D (14 on metformin (Metþ), 14 not on metformin (Met ), but 3 on other antidiabetic drugs) patients matched 3 : 1 to controls (ND, n1⁄484) based on age, sex and BMI.”
BackgroundCosta-Dookhan, K. A. (2020) · TSpace (University of Toronto)
Mikrobiom und Stoffwechsel beim polyzystischen Ovarialsyndrom (PCOS)
Heizmann, W. R., & Keck, C. (2021) · Der Gynäkologe · doi:10.1007/s00129-021-04829-x
Effect of oral antihyperglycemic drugs on purine metabolism
Паневин, Т. С. (2021) · Diabetes Mellitus · doi:10.14341/dm12756 · Cited by 1
Fuel rod behavior during Test PCM-4
Johnson, R. L., Lassahn, P. L., Martinson, Z. R., Sparks, D. T., & Schwieder, D. (1979)
Rare and Underappreciated Causes of Polycystic Ovarian Syndrome
Sacerdote, A. S. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.101946 · Cited by 2
“DOI: 10.3390/ nu12010235 [55] de la Cuesta-Zuluaga J, Mueller NT, Corrales-Agudelo V, Velásquez-Mejía EP, Carmona JA, Abad JM, et al. Metformin is associated with higher relative abundance of mucin-degrading Akkermansia muciniphila and several short-chain fatty acid-producing microbiota in the gut.”
BackgroundInfluentialHan, J. J. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.737127674.793570321
Metformine et flore intestinale
A, F. (2017) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(17)30018-4
Microbial Drug Interactions and Human Health
Ilhan, Z. E., & Herbst‐Kralovetz, M. M. (2022) · Royal Society of Chemistry eBooks · doi:10.1039/9781839160950-00120
If drugs with metabolic action affect the intestinal microbiota. Literature review
Fadieienko, G. D., Gridnyev, O., & Gridneiva, S. V. (2022) · Modern Gastroenterology · doi:10.30978/mg-2022-1-37
Gut dysbiosis: A pathway to glucose dysregulation?
Lawal, Y. (2022) · Journal of Current Research in Scientific Medicine · doi:10.4103/jcrsm.jcrsm_48_21
Influence of Antibiotic Use on the Effectiveness and Safety of Immune Checkpoint Inhibitors
Minamishima, T., Hida, H., Miyazaki, M., Kon, S., Senzaki, K., Nagai, T., & Yamada, K. (2022) · Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) · doi:10.5649/jjphcs.48.173
Demidova, T. Y., & Teplova, A. S. (2024) · Voprosy Pitaniya · doi:10.33029/0042-8833-2024-93-1-33-43
Rojas-Velázquez, D., Kidwai, S., Kraneveld, A. D., Tonda, A. P., Oberski, D. L., Garssen, J., & Lopez‐Rincon, A. (2024) · Figshare · doi:10.6084/m9.figshare.25001638
Walker, R. L., Vlamakis, H. C., Lee, J. W. J., Besse, L. A., Xanthakis, V., Vasan, R. S., Shaw, S. Y., & Xavier, R. J. (2021) · Figshare · doi:10.6084/m9.figshare.17254314
Customised Microbiome Restoration Approaches in Older People: Perspectives and Therapeutic Prospects
Rajalakshmi, M., Vijayalakshmi, P., & Indu, S. (2024) · Springer eBooks · doi:10.1007/978-981-99-8803-7_10 · Cited by 1
Metformin: A Potential Drug for COVID-19
Bettadapura, A. D. S., Puttalingaiah, S., Koushik, A. B., & Gowda, J. (2024) · Indian Journal of Medical Biochemistry · doi:10.5005/jp-journals-10054-0230
Immunological Insights into Healthy Aging: The Impact of BCG Vaccination
Bulut, O. P. (2024) · Radboud University Press eBooks · doi:10.54195/9789493296718
Dąbkowska, D., Mioskowska, A., Szydziak, J., Hrapkowicz, A., Janowska, K., Szeidl, O., Rehan, D., & Wołoszczak, J. (2025) · Journal of Education Health and Sport · doi:10.12775/jehs.2025.77.57110
“Metformin can increase the number of Lactobacillus and Akkermansia in mice and diabetic patients, which affects the integrity of the gut barrier [55].”
The importance of the gut microbiota in the onset and development of obesity
Lazarchuk, I., Plizga, W., Sydor, M., Stołecka, G., Barzak, B., Lipska, P. O., Hankus, K., Pytrus, T., & Woźniak, S. (2024) · Medical Journal of Cell Biology · doi:10.2478/acb-2024-0022
Zariyah, H., & Pramono, A. (2025) · Journal of Nutrition College · doi:10.14710/jnc.v14i2.48176
Abdallah, H., Idenyi, J. N., Adeyemi, A., Abanikannda, M. F., Huber, D., Guerrero-Toledo, F. D. M., Gannam, A. L., Sealey, W. M., Igwe, D. O., & Eya, J. C. (2025) · Animal Feed Science and Technology · doi:10.1016/j.anifeedsci.2025.116387 · Cited by 1
Alteration of gut microbiota composition in patients with prediabetes and type 2 diabetes mellitus
Александровна, М. О., Алексеевич, Т. А., Олеговна, Щ. А., Martirosian, N. S., Кузина, И. А., Валерьевна, Г. Е., Эдуардовна, Т. М., Акрамовна, Э. Э., & Petunina, N. A. (2025) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2025-032
Rachwał, K., Mierczak, K., & Popławski, T. (2025) · Acta gastro-enterologica belgica · doi:10.51821/88.1.13037
Wang, X., Ma, N., Chen, Q., & Wu, Y. (2025) · medRxiv · doi:10.1101/2025.07.10.25331293
Aljohani, N., Aljohani, A., Alamir, N. A. Y., jarah, M. H. A. A., Aljohani, K. A., & Hassan, H. M. (2025) · Saudi Journal of Medicine and Public Health · doi:10.64483/202522264
“For example, metformin treatment is associated with an increase of Akkermansia muciniphila and SCFA-producing bacteria, which could be responsible for the improvement in glucose-lowering and anti-inflammatory effects (Wu et al., 2020; de la Cuesta-Zuluaga et al., 2017).”
The Investigation into Correlation between Type 2 Diabetes Mellitus and the Gut Microbiota
Liu, S., & Zhu, A. M. (2025) · Open Journal of Endocrine and Metabolic Diseases · doi:10.4236/ojemd.2025.1511022
Al‐Muhanna, F., Dowdell, A. K., Eleq, A. H. A., Baker, W. I. A., Brooks, A., Al-Sultan, A. I., Al-Rubaish, A. M., Alkharsah, K. R., Sulaiman, R. M., Al-Quorain, A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26553632
Cheng, X., Zhang, Y., Li, Y., Wu, Q., Wu, J., Park, S.-K., Guo, C., & Lu, J. (2022) · Figshare · doi:10.6084/m9.figshare.21559402
Al‐Muhanna, F., Dowdell, A. K., Eleq, A. H. A., Baker, W. I. A., Brooks, A., Al-Sultan, A. I., Al-Rubaish, A. M., Alkharsah, K. R., Sulaiman, R. M., Al-Quorain, A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26553650
Al‐Muhanna, F., Dowdell, A. K., Eleq, A. H. A., Baker, W. I. A., Brooks, A., Sultan, A. I. A., Al-Rubaish, A. M., Alkharsah, K. R., Sulaiman, R. M., Al-Quorain, A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26553644
Al‐Muhanna, F., Dowdell, A. K., Eleq, A. H. A., Baker, W. I. A., Brooks, A., Al-Sultan, A. I., Al-Rubaish, A. M., Alkharsah, K. R., Sulaiman, R. M., Al-Quorain, A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26553653
Al‐Muhanna, F., Dowdell, A. K., Eleq, A. H. A., Baker, W. I. A., Brooks, A., Al-Sultan, A. I., Al-Rubaish, A. M., Alkharsah, K. R., Sulaiman, R. M., Al-Quorain, A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26553638
Al‐Muhanna, F., Dowdell, A. K., Eleq, A. H. A., Baker, W. I. A., Brooks, A., Al-Sultan, A. I., Al-Rubaish, A. M., Alkharsah, K. R., Sulaiman, R. M., Al-Quorain, A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26553635
Rojas-Velázquez, D., Kidwai, S., Kraneveld, A. D., Tonda, A. P., Oberski, D. L., Garssen, J., & Lopez‐Rincon, A. (2024) · Figshare · doi:10.6084/m9.figshare.26667900
Healthy life-style interventions to attain disease modifications in acquired epilepsy
Kebede, V. (2023) · Open Research Online (The Open University) · doi:10.21954/ou.ro.00017166
Zhu, X., Shen, J., Feng, S., Huang, C., Wang, H., Huo, F., & Liu, H. (2023) · Figshare · doi:10.6084/m9.figshare.23265023
Rojas-Velázquez, D., Kidwai, S., Kraneveld, A. D., Tonda, A. P., Oberski, D. L., Garssen, J., & Lopez‐Rincon, A. (2024) · Figshare · doi:10.6084/m9.figshare.25001746
Walker, R. L., Vlamakis, H. C., Lee, J. W. J., Besse, L. A., Xanthakis, V., Vasan, R. S., Shaw, S. Y., & Xavier, R. J. (2021) · Figshare · doi:10.6084/m9.figshare.17254311
Burnham, C. M., McKenney, E. A., Heugten, K. A., Minter, L. J., & Trivedi, S. (2023) · Figshare · doi:10.6084/m9.figshare.22774208
Al‐Muhanna, F., Dowdell, A. K., Eleq, A. H. A., Baker, W. I. A., Brooks, A., Al-Sultan, A. I., Al-Rubaish, A. M., Alkharsah, K. R., Sulaiman, R. M., Al-Quorain, A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26553647
Al‐Muhanna, F., Dowdell, A. K., Eleq, A. H. A., Baker, W. I. A., Brooks, A., Al-Sultan, A. I., Al-Rubaish, A. M., Alkharsah, K. R., Sulaiman, R. M., Al-Quorain, A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26553656
Al‐Muhanna, F., Dowdell, A. K., Eleq, A. H. A., Baker, W. I. A., Brooks, A., Al-Sultan, A. I., Al-Rubaish, A. M., Alkharsah, K. R., Sulaiman, R. M., Al-Quorain, A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26553659
Al‐Muhanna, F., Dowdell, A. K., Eleq, A. H. A., Baker, W. I. A., Brooks, A., Al-Sultan, A. I., Al-Rubaish, A. M., Alkharsah, K. R., Sulaiman, R. M., Al-Quorain, A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26553641
The Role of the Gut Microbiome in Modulating Arterial Dysfunction With Aging
Greenberg, N. (2024) · CU Scholar (University of Colorado Boulder)
Effect of long-term dietary fat quality on metabolic health with a special focus on dairy fat
Unger, A. L. (2021) · ScholarWorks -A service of University of Vermont Libraries (University of Vermont)
Gut Microbiome-Targeted Interventions for Improving Age-Related Arterial Dysfunction
Longtine, A. G. (2023) · CU Scholar (University of Colorado Boulder)
Gut microbiota: a link between diet and cardiometabolic health
Galié, S. (2021) · Rovira & Virgili repository
Bhunia, S., Adhikari, N., Chakra, B. K., Ghosh, S., Jha, S. K., Debnath, I., Bhowmik, M., Mallick, S., Basak, P., Das, R., et al. (2025) · Medicine in Microecology · doi:10.1016/j.medmic.2025.100163
Zhou, Y., Zhang, Q., Du, X., Song, Y., & Liu, Y. (2026) · Current Nutrition & Food Science · doi:10.2174/0115734013423814251127064733
Metadata
- Authors
- de la Cuesta-Zuluaga, J., Mueller, N. T., Corrales-Agudelo, V., Velásquez-Mejía, E. P., Carmona, J. A., Abad, J. M., & Escobar, J. S.
- Affiliations
- Vidarium—Nutrition, Health and Wellness Research Center, Grupo Empresarial Nutresa, Medellin, Colombia
- Johns Hopkins University (US)
- Vidarium - Centro de Investigación en Nutrición Salud y Bienestar (CO)
- Dinámica I.P.S.—Especialista en Ayudas Diagnósticas, Medellin, Colombia
- EPS y Medicina Prepagada Suramericana S.A., Medellin, Colombia
- Corresponding author
- Escobar, Juan S.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-11-14
- Volume
- 40
- Issue
- 1
- Pages
- 54-62
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2553515186
- Cited by
- 704
- References
- 40
- Citations by year
- 2026: 55 · 2025: 69 · 2024: 86 · 2023: 80 · 2022: 106 · 2021: 78 · 2020: 87 · 2019: 62 · 2018: 45 · 2017: 33 · 2016: 1
- FWCI
- 24.42
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Dentistry › Periodontics › Oral microbiology and periodontitis research
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- metformin, Akkermansia muciniphila, gut microbiota, short-chain fatty acids, type 2 diabetes, mucin degradation, Butyrivibrio, Bifidobacterium bifidum, Megasphaera, Prevotella, Clostridiaceae, Enterococcus casseliflavus, fecal microbiota composition, glycemic control
- MeSH terms
- Gastrointestinal Microbiome, Adolescent, Adult, Colombia, Diabetes Mellitus, Type 2, Fatty Acids, Volatile, Feces, Female, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Mucins, RNA, Ribosomal, 16S, Case-Control Studies, Verrucomicrobia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.